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Abstract
Schizophrenia is a heritable disorder with substantial public health impact. We conducted a multi-
stage genome-wide association study (GWAS) for schizophrenia beginning with a Swedish
national sample (5,001 cases, 6,243 controls) followed by meta-analysis with prior schizophrenia
GWAS (8,832 cases, 12,067 controls) and finally by replication of SNPs in 168 genomic regions
in independent samples (7,413 cases, 19,762 controls, and 581 trios). In total, 22 regions met
genome-wide significance (14 novel and one previously implicated in bipolar disorder). The
results strongly implicate calcium signaling in the etiology of schizophrenia, and include genome-
wide significant results for CACNA1C and CACNB2 whose protein products interact. We
estimate that ～8,300 independent and predominantly common SNPs contribute to risk for
schizophrenia and that these collectively account for most of its heritability. Common genetic
variation plays an important role in the etiology of schizophrenia, and larger studies will allow
more detailed understanding of this devastating disorder.
Keywords
schizophrenia; genetics; genome-wide association; meta-analysis
Schizophrenia is an idiopathic mental disorder with substantial morbidity, mortality, and
personal and societal costs. 1-3 An important genetic component is indicated by a sibling
recurrence risk ratio of 8.6, high heritability estimates (0.64 in a national family study,0.81
in a meta-analysis of twin studies, and 0.23 estimated directly from common SNPs), and
prior genomic findings. 4-8
Although the rationale for genomic searches is strong, there are only a handful of robust
empirical findings for schizophrenia. Genome-wide linkage studies to date have been
inconclusive, 9 and no compelling Mendelian variants have been identified.8 Eight rare copy
number variants of strong effect (genotypic relative risks 4-20)with consistent replication
have been described (e.g., 16p11.2 and 22q11.21); however, these associations are generally
not disease-specific and can also be associated with autism, mental retardation, or
epilepsy. 8Initial exome sequencing studies have not yet identified specific variants of
unequivocal genome-wide significance 9-13 although larger studies are in progress. Prior
GWAS for common variation have yielded statistical evidence for ～10 genomic regions8
including the major histocompatibility complex (MHC) 14-16 along with MIR137 and targets
of miR-137. 17
The prior studies contained indications that more common variant associations were likely
to be discovered with larger sample sizes. 13,17,18 We therefore sought to increase
substantially the number of cases using a multistage GWAS.
Results from Sweden
We analyzed genome-wide data in 5,001 schizophrenia cases and 6,243 controls from a
population-based sampling frame in Sweden (N=11,244, Table 1). Most subjects (57.4%)
have never been previously reported. Following genotyping and imputation with the 1000
Genomes Project Phase 1 reference panel, the genetic data consisted of allelic dosages for
9,871,789 high-quality polymorphic SNPs. Given that this imputation panel is based on
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>800 chromosomes of European ancestry and includes the detail afforded by genome
sequencing, we anticipated increased power in finding and describing association signals.
Indeed, we observed 10,201 SNPs and 187 genomic regions with P < 1×10−5 using 1000
Genomes imputation compared with 1,594 SNPs and 133 regions for HapMap3 imputation
(counts include only one region from the MHC).
The resulting λGC was 1.075 and λ1000 (references 19-21) was 1.013. Quantile-quantile and
Manhattan plots are given in Supplemental Figures 5-6. For association with schizophrenia,
312 SNPs met a genome-wide significance threshold of 5×10−8 (reference 22). These SNPs
were in two genomic regions (Supplemental Figure 7): 241 SNPs in the MHC region
(chr6:28,502,794-32,536,501, minimum P=4.07×10−11 at rs115939516) and 71 SNPs from
chr2:200,715,388-201,040,981 (minimum P=3.33×10−10 at rs35220450). We replicated the
MHC association reported in prior studies. 14-17 The chr2 association with schizophrenia is
novel, shows highly consistent effects in the Sw1-6 genotyping batches and encompasses
C2orf69, C2orf47, C2orf60, and TYW5.
Sweden + PGC
We re-analyzed the PGC schizophrenia data using 1000 Genomes imputation (8,832 cases
and 12,067 controls, excluding Swedish samples). 17 Five regions met genome-wide
significance: the MHC locus (chr6:27,261,324-32,610,445, minimum P=2.18×10−10),
AS3MT-CNNM2-NT5C2 (chr10:104,635,103-104,960,464, minimum P=4.29×10−10),
MAD1L1 (chr7:2,005,747-2,098,238, minimum P=2.40×10−8), RP11-586K2.1,
(chr8:89,585,639-89,760,620, minimum P=2.37×10−8), and SNPs nearTCF4
(chr18:53,311,001-53,423,307, minimum P=3.00×10−8).
We then conducted a meta-analysis of the Swedish and independent PGC schizophrenia
samples using the same quality control, imputation, and analysis pipeline. This GWAS
meta-analysis of 13,833 schizophrenia cases and 18,310 controls (Table 1) afforded power
to detect genotypic relative risks of 1.10-1.14 for reference allele frequencies 0.15-0.85
(power=0.8, α=5×10−8, log-additive model). We evaluated the comparability of the Swedish
and PGC studies using sign tests: of 608 SNPs selected from the PGC results with P <
0.0001 and in approximate linkage equilibrium, 62.6% had logistic regression beta
coefficients with the same sign in the Swedish results, an observation highly inconsistent
with the null (P=2.2×10−10). λGC was 1.186 and λ1000 was 1.012, values consistent with a
polygenic pattern of association but not gross inflation due to technical artifacts. 20 Quantile-
quantile and Manhattan plots are shown in Supplemental Figure 11 and Figure 1, and
genome-wide significance was exceeded by 3,538 SNPs in 12 genomic regions.
We used risk score profiling14,17 to evaluate the capacity of 130K SNPs derived from the
PGC to predict case-control status in the Swedish samples. These SNPs were selected for
high-confidence and approximate linkage equilibrium but without regard to association P
value. As shown in Figure 2, PGC risk scores had a highly significant capacity to predict
case-control status in the independent Swedish samples (P values from 10−26 – 10−114). The
increased sample size allowed improved risk profile prediction as more of the SNPs in the
lower bins are replicable signals. The threshold at which the explanatory power of these risk
profile SNPs plateaus has decreased with increasing sample size: PT=0.1 in Figure 2, 0.2 in
the PGC report, and no plateau in the ISC study). 14,17 Although the mean risk profiles were
highly significantly different between cases and controls, the distributions overlap
substantially (Supplemental Figure 9) and are insufficient for diagnostic purposes (area
under the receiver operating characteristic curve 0.65). However, these results strongly
support the comparability of the Swedish and PGC samples and the validity of the meta-
analysis.
Ripke et al. Page 3
Nat Genet. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
GWAS often omit the X chromosome (chrX). This omission is problematic as chrX is
approximately as large as chromosome 8 and is enriched for genes important in brain
development. Using a previously described approach, we imputed genotyped chrX SNPs to
the 1000 Genomes reference panel. 23 Joint analysis of all subjects as well as males and
females separately revealed no association exceeding genome-wide significance. The
strongest association (rs12845396, chrX:6,029,533, P=3.46×10−7) was in an intron of
NLGN4X (neuroligin 4), a gene previously implicated in mental retardation and autism, and
there were multiple possible signals nearMECP2(causal to Rett syndrome, P=9.3×10−6).
GWAS results generally do not lie in protein coding regions. 24 A recent report suggested
that most SNPs in the NHGRI GWAS catalog 24 were in or in perfect LD with DNase 1
hypersensitive sites. 25 We thus evaluated whether the Sweden + PGC results had significant
overlap with DNase 1 hypersensitive sites generated as part of the ENCODE project. 26 We
did not find evidence of enrichment (Supplemental Table 8 and Supplemental Figure 10).
However, this negative result is strongly qualified by the lack of DNase 1 hypersensitivity
data directly relevant to psychiatric disorders.
Sweden + PGC + replication
We then obtained association results for SNPs in 194 genomic regions in six independent
samples for a total sample size of over 21,000 cases and 38,000 controls(Table 1). The
genomic regions for which replication genotypes were sought were identified using LD
clumping defined by LD (r2> 0.5) and a minimum P < 1×10−5 in the Sweden-PGC meta-
analysis. Only one MHC SNP was included. The Sweden-PGC meta-analysis and
replication results were highly concordant with 76.3% of the logistic regression beta
coefficients having the same direction of effect (sign test P=1.5×10−17). Indeed, of the top
100 SNPs in the Sweden-PGC meta-analysis, 90% had the same sign in the replication
results. This result strongly suggests that many more loci will achieve genome-wide
significance with further increases in sample size.
Table 2 shows the combined results in which 24 regions reached genome-wide significance.
As two pairs of these regions overlap (chr1:243Mb and chr5:152Mb), there are associations
with schizophrenia in 22 genomic regions. Three additional regions nearly met genome-
wide significance (rs4380187 near ZNF804A P=5.66×10−8, rs4523957 in SRR
P=5.69×10−8, and rs6550435 near TRANK1 P=5.86×10−8 which also had P=9×10−6 in a
bipolar disorder GWAS). 27
Of these 22 regions (Table 3), five regions have been reported previously as meeting
genome-wide significance for schizophrenia (MHC, C10orf26, DPYD-MIR137, SDCCAG8,
and MMP16) and two for schizophrenia, bipolar disorder, and a combined phenotype
(CACNA1C and ITIH3-ITIH4). 14-17,27-29 For the remaining 15 regions, we now find
genome-wide significance for a locus previously implicated only for bipolar disorder
(NCAN)30 along with 14 novel regions.
Themes
We highlight four themes from these results (see also Supplemental Table 9). First, these
results implicate calcium signaling in the etiology of schizophrenia. As in prior studies of
bipolar disorder and schizophrenia, 17,27,28 we found genome-wide significant support for
CACNA1C (Cav1.2, P=5.2×10−12 at the intronic SNP rs1006737). Intriguingly, we
identified a novel genome-wide significant association for CACNB2 (P=1.3×10−10 at the
intronic SNP rs17691888) which encodes the β2 subunit of L-type calcium channels (Cav
β2). A gene-set test supported the involvement of calcium channel subunits in the etiology
of schizophrenia (Supplemental Table 7).
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In L-type calcium channels, the α1c subunit forms the transmembrane pore, and directly
interacts with the intracellular β2 subunit. 31 The β2 subunit also antagonizes an endoplasmic
reticulum retention motif on the α1c subunit to facilitate transport to the plasma
membrane. 32Additional genes with genome-wide significant evidence were implicated
based on membership in a proteomic network centered on Cav2 (reference 33): the protein
products of ACTR1A (α-centractin), the divalent metal cation transporter CNNM2
(P=3.7×10−13, chr10:103,009,986-105,512,924), and CACNB2. A broad genomic region
containing the calcium binding protein troponin C (TNNC1) also met genome-wide
significance (P=1.1×10−8) as well as three calcium homeostasis modulator genes
(CALHM1, CALHM2,and CALHM3 in same chr10 region as CNNM2).
The genetics and biology of calcium channels have been the subject of considerable
investigation owing to their importance in fundamental neuronal processes and human
diseases. L-type voltage-gated calcium channels are involved in learning, memory, and
synaptic plasticity, and CACNA1C knock-out mice show notable deficits in long term
potentiation. 34-37 Calcium “channelopathies” include mutations in CACNA1C and
CACNB2 that cause Brugada syndrome types 3 and 4 (OMIM #611875 and #611876). 38In
addition, Timothy syndrome (OMIM #601005), caused by mutations in CACNA1C, is a
multisystem disorder including cognitive impairment and autism spectrum disorder. 39
Although Mendelian disorders are usually characterized by persistent pathological features,
Mendelian calcium channelopathies can have episodic phenomena perhaps reminiscent of
the episodic nature of psychotic disorders – for example, intermittent hypoglycemia and
hypocalcemia in Timothy syndrome (CACNA1C), episodic ataxia (CACNA1A, CACNB4),
migraine (CACNA1A), epilepsy (CACNA1H, CACNB4), periodic paralysis (CACNA1S),
and malignant hyperthermia (CACNA1S, CACNA2D1). 31,39
GWAS findings for schizophrenia have converged on genome-wide significant evidence for
a calcium channel functional complex that has also been implicated in bipolar disorder and
autism. These genomic results support increased attention to this pathway, and suggest
hypotheses for clinical translation. Multiple approved medications act at calcium channels
including some antipsychotics (e.g., pimozide) along with adjuvants for treatment non-
response for schizophrenia and bipolar disorder (e.g., the calcium channel blockers
verapamil and nifedipine). It is possible that drugs that act on the protein products of
CACNA1C and CACNB2 for a different therapeutic indication could be “re-purposed” for
the treatment of schizophrenia. For example, there has been at least one clinical trial of the
efficacy of isradipine in bipolar disorder (an approved antihypertensive acting at the protein
product of CACNA1C, R Perlis, personal communication). In addition, given that many
approved antipsychotics increase the cardiac QT interval, genetic variation in calcium
channel genes might identify individuals at higher risk of sudden cardiac death. 40,41
Second, as reported previously, 14-17 the strongest association P=9.1×10−14)with
schizophrenia is in the extended MHC (chr6:25-34Mb), a region of both exceptional
importance and complexity. The MHC comprises 0.3% of the genome but contains 1.5% of
the genes in OMIM 42 and 6.4% of genome-wide significant SNP associations in the
NHGRI GWAS catalog. 24 It is the second most gene-dense genomic region and has high
LD over its extent. We speculate that these features (high gene density and strong LD)
combined with the polygenicity of schizophrenia lead to the strong association but will also
complicate efforts to identify causal variation. Genome-wide significant associations with
schizophrenia extend over 7Mb, but Supplemental Figure 12 suggests that larger samples
may resolve this association into sub-regions near TRIM26 (tripartite motif containing 26,
chr6:30.1Mb) and the HLA-DRB9 unprocessed pseudogene (chr6:32.4Mb, intergenic HLA-
DRA – HLA-DRB5).
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Third, multiple genomic lines of evidence support a role for MIR137 in the etiology of
schizophrenia. We provide increased support for a common variant association located
upstream of the MIR137 transcript (P=1.7×10−12, Supplemental Figure 13). Fourteen genes
in the regions in Table 3 have miR-137 target sites predicted by TargetScan (v6.2) 43
(C6orf47, HLA-DQA1, TNXB, VARS, C10orf26, CACNA1C, DPYD, CACNB2, TSSK6,
NT5DC2, PITPNM2, SBNO1, ZEB2, and PRKD3). Using gene-set analysis, we evaluated
whether genes with predicted miR-137 target sites were enriched for smaller association P
values. We confirmed the PGC result 17 and extended the finding by showing more robust
enrichment in afar larger set of genes with predicted miR-137 target sites (Supplemental
Table 7). In addition, our unpublished work shows enrichment for smaller GWAS P-values
in genes down-regulated following over-expression of miR-137 in human neural stem cells
(Collins, in preparation). Given the role of miR-137 in fundamental neuronal
processes, 44-46 these results support investigation of pathways influenced by miR-137in
regard to a role in the pathogenesis of schizophrenia.
The SNP with the strongest association to schizophrenia (rs1198588) is 39kb upstream of
MIR137, and might regulate the transcription of MIR137. However, this has not been
proven experimentally and there is another candidate gene in the region. rs1198588 is in an
LD block that includes DPYD (169kb upstream of rs1198588),and rs1198588 is a
significant local expression quantitative trait locus (eQTL) with DPYD. We note that DPYD
also contains a predicted miR-137 target site. An exome sequencing study reported two
putative functional de novo variants in DPYD in cases with schizophrenia. 11
Fourth, 13 of the 22 regions in Table 3 contain long intergenic non-coding RNAs
(lincRNAs). lincRNAs have multiple known or suspected functions including epigenetic
regulation and development. 47 Using pathway analysis,48 there was modest enrichment
(P=0.06) for smaller association P values in a conservative set of lincRNAs derived from
sequencing of poly-A RNA from multiple tissues. 47 This observation is consistent with a
general role for GWAS findings in the regulation of gene expression rather than alteration of
protein sequence. eQTLs 49,50 overlap with SNPs implicated by GWAS over all traits 51-53
as well as for specific traits like height, adiposity, cardiovascular risk factors, chemotherapy-
induced cytotoxicity, autism, schizophrenia, and Crohn's disease. 54-61An estimated 55% of
eQTL SNPs lie in DNase I hypersensitivity sites (a marker for open chromatin subject to
transcriptional regulation) and 77% of SNPs implicated in GWAS are in or in high LD with
SNPs inDNase I hypersensitivity sites. 25,62,63
Genetic architecture
There has been considerable debate about the genetic architecture of schizophrenia. We
estimated the proportion of variance in liability to schizophrenia explained by SNPs using
GCTA. 64 Traditional genetic epidemiological studies use the phenotypic resemblance of
relatives to estimate the proportion of variance in liability using theoretic resemblance
assumptions. GCTA uses genome-wide SNP genotypes to calculate the heritability in the
population from the identity-by-state relationships for each pair of individuals. Using the
PGC schizophrenia data, we previously estimated the SNP heritability of schizophrenia at
0.23 (SE 0.01) using HapMap3 imputation and assuming a population risk of 0.01. 7 Using
the same imputation reference and population risk, SNP heritability was substantially higher
in the Swedish samples (0.32, SE 0.03) possibly due to the greater phenotypic and genetic
homogeneity in the Swedish sample compared to the PGC samples of mixed European
ancestry. We obtained a similar estimate of SNP heritability using 1000 Genomes imputed
data (0.33, SE 0.03, population risk 0.01). For a population risk of 0.004, 4,65 SNP
heritability was 0.26 (SE 0.02) using HapMap3 and 0.27 (SE 0.02) using 1000 Genomes
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imputation. Partitioning of the SNP-heritability by minor allele frequency is consistent with
80% of the signal reflecting causal variants with MAF > 0.1 (Supplemental Table 5).
To complement the GCTA analyses, we also applied ABPA (approximate Bayesian
polygenic analysis) 66 to the Sweden + PGC results. Compared to GCTA, ABPA yielded
somewhat larger but generally congruent estimates of variance in liability to schizophrenia
using HapMap3 data: 0.43 for population risk of 0.01 (95% credible interval 0.38-0.48) and
0.34 for population risk of 0.004 (95% credible interval 0.31-0.37).
The Bayesian framework used by ABPA also allows simultaneous estimation of the number
of independent SNP loci that contribute to risk for schizophrenia. Here, we assume that the
number of genome-wide significant SNP associations and the amount of variance they
explain in the Sweden + PGC results reflect only partly the underlying genetic architecture
of schizophrenia due to inadequate sample size. Using 1000 Genomes results for Sweden +
PGC and assuming population risk of 0.01, we estimated that 8,300 independent SNPs
contribute to the genetic basis of schizophrenia and that these SNPs account for 50% of the
variance in liability to schizophrenia (95% credible intervals 6,300-10,200 for the number of
SNPs and 0.45-0.54 for total variance explained). We stress that these estimates must be
interpreted in the context of the assumptions of ABPA and the strengths and weaknesses of
the input data. Additional analyses (not shown) indicate that most of the signal was derived
from SNPs with allele frequencies > 0.1; low-frequency imputed SNPs were not generally
inferred to be associated with schizophrenia. Figure 3 compares ABPA estimates of the
genetic architecture of schizophrenia and four biomedical diseases. 66 There are similarities
across the estimates for these complex traits as all are relatively highly polygenic, and
common SNPs explain substantial proportions of variation. However, these results suggest
that the genetic architecture of schizophrenia is left-shifted with greater numbers of SNPs
with smaller effects.
We previously estimated the heritability of schizophrenia in Sweden to be 0.64 (95% CI
0.617-0.675) using a national pedigree sample of 9.0M individuals,5 and a Danish national
pedigree study of 2.6M individuals reported a similar estimate (0.67, 95% CI
0.65-0.71). 5,67Using the 1000 Genomes data with population risk of 0.01, the variance in
liability estimate from GCTA accounts for 52% of the heritability (0.33/0.64) and ABPA
accounts for 78% of the heritability (0.50/0.64). Imprecision is inherent to these estimates
and future work or the use of a twin meta-analytic estimate of the heritability of
schizophrenia (0.81, 95% CI 0.73-0.90) 6 could revise these estimates downward. However,
despite the use of different assumptions and methods, these estimates converge on a crucial
qualitative implication: causal variants tagged by common SNPs make substantial
contributions to the risk for schizophrenia.
Conclusions
These results provide deeper insight into the genetic architecture of schizophrenia than ever
before. We find support for 22 common variant loci (14 novel) that highlight biological
hypotheses for further evaluation. Some findings have immediate translational relevance.
Larger studies are highly likely to uncover more common variant associations as argued
elsewhere. 8,18,68,69
Common variation is an important (and perhaps predominant) genetic contributor to risk for
schizophrenia. We estimated that 6,300-10,200 independent and mostly common SNPs
contribute to the etiology of schizophrenia. As one gene or structural element could contain
multiple independent associations, that the number of number of genes ultimately
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determined to harbor causal variation for schizophrenia will be smaller, and we expect that
these genes will implicate one or more biological pathways fundamental to disease risk.
Moreover, these thousands of independent loci appear to account for a considerable fraction
of the heritability of schizophrenia. It is possible that the commonly used phrase “missing
heritability” lacks precision. Indeed, if thousands of SNPs underlie schizophrenia, a
statistical models containing a handful of SNPs is unlikely to account for more than a small
fraction of the heritability. 70 Ourresults imply that the genetic architecture of schizophrenia
is not dominated by uncommon variation. However, a balanced plan of attack should include
well-powered searches for rare, private, or de novo genetic variation of strong effect given
that such variants are probably more tractable to current molecular methods.
Power calculations are a fundamental component of the design of genetic studies. However,
relatively extensive knowledge of genetic architecture is essential for power calculations to
have maximum utility for study planning. We used the ABPA estimates of the posterior
distribution of genotypic relative risks (Figure 3) to inform power calculations by estimating
the numbers of independent loci that could be detected for different sample sizes
(Supplemental Table 6 and Supplemental Figure 8). For example, for 60,000 schizophrenia
cases and 60,000 controls, ABPA results project that hundreds of independent SNP loci
would reach genome-wide significance (mean of 794 SNPs, 95% credible interval 362-1154
SNPs).
Thus, for the first time, we now have a clear path to increased knowledge about the etiology
of schizophrenia via application of standard, off-the-shelf genomic technologies for
elucidating the effects of common variation. We suggest that a relatively thorough
enumeration of the genomic loci conferring risk for schizophrenia (the “parts list”) should be
a priority for the field. 8 Identifying all loci would surely be an exercise in diminishing
returns. However, we propose a goal for the field: identification of the top 2,000 loci (for
example) might be sufficient confidently and clearly to reveal the biological processes that
mediate risk and protection for schizophrenia. Achievement of this goal would provide a
strong empirical impetus for targeted biological and genetic research into the precise
molecular basis of risk for schizophrenia, stratification of at-risk populations (e.g., psychotic
prodrome), and appropriate cellular measure for evaluation of novel therapeutics. As
indicated by our findings, greater knowledge of the genetic basis of schizophrenia can
converge on increasingly specific neurobiological hypotheses that can be prioritized for
subsequent investigation.
Online Methods
Overview
We present here the pre-planned principal analyses for this project. In order to advance
knowledge of schizophrenia, a minority of samples were included in prior reports.
Genotyping was conducted in six batches (denoted Sw1-Sw6) with total sample sizes of
464, 694, 1498, 2388, 4461, and 2345. Genotypes were generated as sufficient numbers of
samples accumulated from the field work in Sweden. The 2009 International Schizophrenia
Consortium report contained GWAS data from the Sw1-2 subjects (N=1158, 9.8% of the
sample before quality control). 14. The 2011 PGC schizophrenia paper also contained
GWAS data from the Sw1-2 subjects plus ～80 SNPs from Sw3-4 in the replication phase. 17
The 2012 Bergen et al. paper had a particular focus contrasting schizophrenia with bipolar
disorder and reported GWAS results from Sw1-4 (N=4044, 42.6% of the full sample). 75
Thus, of the total sample of 11,850 Swedish subjects before quality control (5,351 cases,
6,509 controls), 57.4% have never been reported previously.
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Subjects
All procedures were approved by ethical committees at the Karolinska Institutet and
University of North Carolina, and all subjects provided written informed consent (or legal
guardian consent and subject assent). Sample collection was from 2005-11.
Cases with schizophrenia were identified via the Swedish Hospital Discharge Register 76,77
which captures all public and private inpatient hospitalizations. The register is complete
from 1987 and augmented by psychiatric data from 1973-86. The register contains ICD
discharge diagnoses 78-80 made by attending physicians for each hospitalization. 81-84 Case
inclusion criteria: ≥2 hospitalizations with a discharge diagnosis of schizophrenia, both
parents born in Scandinavia, and age ≥18 years. Case exclusion criteria: hospital register
diagnosis of any medical or psychiatric disorder mitigating a confident diagnosis of
schizophrenia as determined by expert review, and included removal of 3.4% of eligible
cases due to the primacy of another psychiatric disorder (0.9%) or a general medical
condition (0.3%) or uncertainties in the Hospital Discharge Register (e.g., contiguous
admissions with brief total duration, 2.2%).
The validity of this case definition of schizophrenia is described at length in the Supplement,
and validity is strongly supported by clinical, epidemiological, genetic epidemiological, and
genetic evidence.
Controls were selected at random from Swedish population registers with the goal of
obtaining an appropriate control group and avoiding “super-normal” controls. 85 Control
inclusion criteria: never hospitalized for schizophrenia or bipolar disorder (given evidence of
genetic overlap with schizophrenia), 5,14,86 both parents born in Scandinavia, and age ≥18
years.
Of the potential cases and controls who were alive and contactable, refusal rates were higher
for cases than for controls (46.7% versus 41.7%). However, these proportions compare
favorably with modern refusal rates in epidemiology (59% for cross-sectional and 44% for
case-control studies), 87,88 and in a recent large Norwegian longitudinal study (58%). 89 For
cases, comorbidity with drug/alcohol abuse or dependence did not predict participation nor
did any subtype of schizophrenia (e.g., paranoid or disorganized types). The sample was
approximately representative of the Swedish populace in regard to county of birth
(Supplemental Figure 4).
Genotyping, quality control, and imputation
DNA was extracted from peripheral blood samples at the Karolinska Institutet Biobank.
Samples were genotyped in six batches at the Broad Institute using Affymetrix 5.0 (3.9%),
Affymetrix 6.0 (38.6%), and Illumina OmniExpress (57.4%) chips according to the
manufacturers' protocols (Supplemental Table 3). Genotype calling, quality control, and
imputation were done in four sets corresponding to data from Affymetrix 5.0 (Sw1),
Affymetrix 6.0 (Sw2-4), and the OmniExpress batches (Sw5, Sw6). Genotypes were called
using Birdsuite (Affymetrix) or BeadStudio (Illumina). The quality control parameters
applied were: SNP missingness < 0.05 (before sample removal); subject missingness <
0.02;autosomal heterozygosity deviation; SNP missingness < 0.02 (after sample
removal);difference in SNP missingness between cases and controls < 0.02; and deviation
from Hardy-Weinberg equilibrium (P < 10−6 in controls or P < 10−10 in cases).
After basic quality control, 77,986 autosomal SNPs directly genotyped on all four GWAS
platforms were extracted and pruned to remove SNPs in LD (r2> 0.05) or with minor allele
frequency < 0.05, leaving 39,239 SNPs suitable for robust relatedness testing and population
structure analysis. Relatedness testing was done with PLINK90 and pairs of subjects with
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π(x00302) > 0.2 were identified and one member of each relative pair removed at random.
Principal component estimation was done with the same collection of SNPs. We tested 20
principal components for phenotype association (using logistic regression with batch
indicator variables included as covariates) and evaluated their impact on the genome-wide
test statistics using λ 19 after genome-wide association of the specified principal component,
and 11 principal components were included in all association analyses.
Genotype imputation was performed using the pre-phasing/imputation stepwise approach
implemented in IMPUTE2 / SHAPEIT (chunk size of 3 Mb and default parameters). 91,92
The imputation reference set consisted of 2,186 phased haplotypes from the full
1000Genomes Project dataset (March 2012, 40,318,245 variants). Evaluation of λGC led to
the removal of SNPs with control allele frequencies < 0.005 or > 0.995, imputation “info”
values < 0.2, or that were genotyped only in the smallest sample set (Sw1). Given that male
sex is a risk factor for schizophrenia, 93 chromosome X imputation was conducted for
subjects passing QC for the autosomal analysis (excluding chrX SNPs with missingness ≥
0.05 or HWE P < 10−6 in females). Imputation was performed separately for males and
females, gene dosages tested for association under an additive logistic regression model
using the same covariates as for the autosomal analysis. All genomic locations are given in
NCBI build 37/UCSC hg19 coordinates.
Statistical analysis
We first analyzed Swedish cases and controls (N=11,244), and then conducted a meta-
analysis with the PGC results for schizophrenia to evaluate our results with respect to the
world's literature (N=20,899 after removing 954 subjects from Sw1-2). 17 To maximize
comparability, the Swedish samples were run through the same analytical pipeline used for
the PGC samples. Association testing was carried out in PLINK using imputed SNP dosages
and the principal components described above as covariates. 22 Meta-analysis was
conducted using an inverse-weighted fixed effects model. 21 To evaluate the comparability
of the Swedish results with those from the PGC schizophrenia study, we used sign tests and
risk score profiling based on sets of carefully selected SNPs. 17
Summarizing regional data using “clumping”
Many GWAS findings implicate an extended region containing multiple significant SNPs.
These are not independent associations but result because of high LD between associated
SNPs. It is useful to summarize these associations in terms of the index SNP with the
highest association and other SNPs in high linkage disequilibrium with the index SNP. To
summarize GWAS findings, we used the following settings in PLINK:
--clump-p1 1e-4 --clump-p2 1e-4 --clump-r2 0.2 --clump-kb 500
to retain SNPs with association P < 0.0001 and r2 < 0.2 within 500 kb windows.
Sign tests
We used sign tests to compare the overall patterns of results between the Swedish and PGC
schizophrenia samples. We used the clumping settings above to derive a filtered set of
SNPs. Due to the strong signal and high linkage disequilibrium in the MHC, only one SNP
was kept from the extended MHC region. We then determined the number of SNPs whose
logistic regression beta coefficient signs were the same between two independent samples.
Under the null, the expectation is that 50% of the signs of these SNPs will be the same
between two independent sets of results. The significance of the observed proportion was
evaluated using the binomial distribution.
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The significance test was done in two ways: selecting SNPs from Sw1-6 results and
evaluating the signs in the independent PGC results, and by reversing the procedure (select
from PGC, evaluate signs in Sw1-6). Similar results were obtained selecting SNPs for: (a) P
< 1×10−5, (b) P < 1×10−6, (c) keeping one SNP every 3 Mb (effectively removing or greatly
minimizing the effects of residual linkage disequilibrium).
Risk score profiles (RPS)
We used RPS 14 as an alternative and complementary way to compare the overall patterns of
results from the PGC schizophrenia analysis (discovery sample) with the independent
Swedish results (target sample). We began by selecting a high-quality, relatively
independent SNPs with unambiguous directions of effects: from the PGC imputed results
file, we made a subset of results containing SNPs with allele frequency 0.02-0.98 and
imputation INFO scores > 0.9. We then removed SNPs in high LD using via clumping (i.e.,
retain all SNPs with r2< 0.25 within 500 kb windows):
--clump-p1 1 --clump-p2 1 --clump-r2 0.25 --clump-kb 500
For RPS, we wished to evaluate SNP effects across the p-value spectrum. Again, due to the
strong signal and high linkage disequilibrium in the MHC, only one SNP was kept from the
extended MHC region.
We used the resulting list from the PGC to calculate schizophrenia risk profile scores in the
independent Swedish samples using the
--score
function in PLINK. We did this 10 times using different subsets of the PGC SNPs selected
by increasing P value thresholds. From the set of filtered SNPs from the PGC, we evaluated
10 different association P thresholds (PT): 0.0001, 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5,
and 1.0 (i.e., include all SNPs). For each of these 10 sets of SNPs derived from the PGC, the
schizophrenia risk profile score (the number of schizophrenia risk alleles weighted by the
logistic regression beta) was calculated for each case and control in Sw1-6. Logistic
regression was then used to test whether Swedish cases had significantly different burden of
schizophrenia risk alleles in comparison to controls (including ancestry principal
components as covariates). To estimate the proportion of variance of case-control status in
the Swedish samples accounted for by the risk profile score from the PGC, we used the
difference in the Nagelkerke pseudo R2 contrasting a logistic regression model containing
the risk profile score plus ancestry covariates with a logistic regression model containing the
covariates alone.
Gene-set analysis
One way to understand polygenic associations for a complex trait is if the implicated genetic
variants are in genes that comprise a biological pathway. Gene-set analysis includes
evaluation of genetic variants in genes that are grouped based on their interacting role in
biological pathways (biological pathway analysis) and genes that share similar cellular
functions (functional gene-set analysis).
We used JAG (Joint Association of Genetic variants, http://ctglab.nl/software) to conduct
gene-set analyses. This method has previously been applied to the International
Schizophrenia Consortium data by Lips et al. 94 JAG tests for the association of specified
gene-sets with schizophrenia as applied to individual-level genotype data which tends to be
more powerful than using summary statistics. JAG constructs a test-statistic for each gene-
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set. JAG includes both self-contained and competitive tests. These two approaches evaluate
different null hypotheses. Statistical significance (Pself and Pcomp) are determined using
permutation. First, the self-contained test evaluates the null hypothesis that a defined set of
genes is not associated with schizophrenia while accounting for the some of the properties of
the SNPs being studied (e.g., LD structure). Second, the competitive test evaluates whether a
specific set of genes has evidence for stronger associations with schizophrenia than
randomly selected sets of control genes (with the latter matched to the former using the same
effective number of SNPs per gene-set). Thus, a competitive test is of the null hypothesis is
that these genes are not more strongly associated than a similar but randomly-selected set of
genes. That is, the comparison is more one to the average degree of association across genes.
The principal comparison is the competitive test, and we present self-contained tests for
completeness. Competitive gene-set tests are more appropriate for a polygenic disease like
schizophrenia because they explicitly prioritize gene-sets that show a greater average degree
of association, over and above the polygenic background, rather than prioritizing larger but
more weakly-enriched gene-sets (as self-contained tests would tend to do).
Replication
We obtained replication association results from six independent samples totaling 7,452
cases, 20,404 controls, and 581 trios (Supplemental Table 4). These subjects are not
included in the Swedish samples or in the PGC mega-analysis. 17 The independent samples
were from SGENE+, 16, CLOZUK, 29 the Irish Schizophrenia Genomics Consortium, 95 the
Psychosis Endophenotype Consortium, 96, and the Multicenter Family Study. 97 After
selecting for P < 1×10−5 in the Sweden and PGC meta-analysis and accounting for linkage
disequilibrium, we requested association results for 194 genomic regions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Manhattan plot of the Swedish and PGC schizophrenia meta-analysis results. The x-axis is
chromosomal position and the y-axis is –log10(P). The red line is the genome-wide
significance level (5×10−8). Gene locations are indicated.
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Figure 2.
Risk score profiling results using the PGC schizophrenia results as the discovery set and the
Sweden data as the testing set. The x-axis shows ten P value thresholds (PT = 10−4, 10−3, …,
1). The y-axis is the Nagelkerke pseudo R2, the proportion of variance in case-control status
explained by the risk score profile. The number atop each vertical bar is the P value for the
capacity of the risk score profile to predict case-control status for that PT.
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Figure 3.
The main figure shows the results of ABPA modeling based on the Sweden + PGC results
(population risk 0.01). The x-axis is the estimated number of SNPs on a log10 scale, and the
y-axis estimates the total variance in liability explained. The results for five conditions are
shown: schizophrenia (this analysis, red) and, for comparison, results from a published
analysis of myocardial infarction (MI, purple), type 2 diabetes mellitus (T2D, blue), celiac
disease (green), and rheumatoid arthritis (RA, teal). 71 The schizophrenia results are based
on 1000 Genomes imputation, and the others on HapMap3 imputation. Color intensity
reflects the probability density with darker colors indicating higher density. Contour lines
show 50% and 95% credible regions for SCZ, and 95% credible regions for the other
diseases. The insets depict estimated SNP distributions for the five disorders: (a) distribution
of SNPs in terms of the variance in liability explained per SNP and (b) the estimated
distribution of SNP genotypic relative risks (GRR). We again stress that multiple qualifiers
are essential in interpreting these estimates.
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Table 1
Subject characteristics and sample sizes.
Feature Cases Controls
 Swedish sample characteristics
 Male sex 0.595 0.512
 Median age at sampling 54 (45-62) 57 (48-65)
 Median hospital admissions for SCZ or SAD 7 (3-15) n/a
 Median total inpatient days 243 (81-696) n/a
 Median years from first to last HDR admission 9.7 (2.9-19.5) n/a
Sample sizes
 Swedish subjects (Sw1-6) 5,001 6,243
 PGC schizophrenia subjects (excluding Sw1-2) 8,832 12,067
 Replication results for up to 168 genomic regions 7,413 19,762
 Total subjects 21,246 38,072
Values in parentheses are inter-quartile ranges. The case group had significantly more males (p < 0.0001) and was significantly younger (p <
0.0001) than controls although these differences were not of large magnitude. The higher median age in controls is in the direction of greater
confidence in control classification (i.e., controls had greater time at risk for psychiatric hospitalization). Cases tended to have had considerable
hospitalizations, inpatient lengths of stay, and years of observation. IQQ=interquartile range, SCZ=schizophrenia, SAD=schizoaffective disorder,
HDR=Hospital Discharge Register.
All cases and controls are independent. The Swedish sample totals N=11,244, the PGC N=20,899, and the replication samples N=27,175. The
Sweden plus PGC meta-analysis is based on N=32, 143. The Swedish sample plus PGC plus replication samples total 59,318. (these counts exclude
511 trios).
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